Leerink Partners Maintains Outperform Rating on United Therapeutics
Leerink Partners maintained its Outperform rating and $725 price target for United Therapeutics. The target implies 36.0% upside from the Oct. 16 close of $533.12.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.